Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein phosphatase magnesium-dependent 1D (PPM1D), commonly referred to as PP2Cδ or WIP1, is a member of the PP2C family of serine/threonine protein phosphatases that serves as a critical negative regulator of the DNA damage response (DDR) (UniProt: P49757). It is induced by p53 in response to stress and functions to return the cell to a homeostatic state by dephosphorylating key proteins such as p53, p38 MAPK, Chk1, and Chk2 (PubMed: 24901554). Overexpression or amplification of the PPM1D gene is observed in various malignancies, including breast and ovarian cancers, where it acts as an oncogene by suppressing tumor-suppressive pathways and promoting cell survival following DNA damage (PubMed: 21135154). Because of its role in dampening the DDR, PPM1D is a high-priority therapeutic target; inhibiting its activity can sensitize cancer cells to chemotherapy and radiotherapy (PubMed: 24901554). Several small-molecule inhibitors, most notably GSK2830371, have demonstrated the ability to selectively inhibit PPM1D and suppress tumor growth in preclinical models (PubMed: 24901554). However, therapeutic development must account for potential safety concerns, including the risk of disrupting normal DNA repair processes in healthy tissues. The target is also associated with Jansky-Diekmann-Vogt syndrome in rare genetic contexts, though its primary clinical interest remains in oncology (NCBI Gene: 8493). Targeting the catalytic domain of PP2Cδ allows for the restoration of p53-mediated apoptosis in p53-wildtype tumors. Current research focuses on improving the potency and pharmacokinetic properties of these inhibitors for clinical transition. Overall, PP2Cδ represents a strategic node for modulating the balance between cell cycle arrest and apoptosis in cancer therapy.
Small molecule inhibition of the phosphatase catalytic activity to restore p53 and p38 MAPK signaling pathways.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein phosphatase magnesium-dependent 1D (PPM1D) (PPM1D).